- Lactoferrin is known for its benefits in immunity, iron absorption, gut health and inflammation
- Traditionally sourced from cow’s milk, lactoferrin has been costly and difficult to produce at scale
- Precision fermentation is enabling animal-free production of both bovine and human lactoferrin
- Start-ups and major food companies are investing in scaling production and expanding applications beyond infant formula
- Women’s health, sports nutrition and next-generation infant nutrition are emerging as key growth opportunities
Described in one study as a ‘miracle molecule’, lactoferrin is an ingredient on the up.
A component of whey protein in the milk of most mammals, it helps to balance iron levels, boost immunity and supports the growth of healthy probiotic bacteria in the digestive system, as well as having antioxidant and anti-inflammatory properties.
Its benefits are well-established with thousands of studies published on it.
Conventionally produced lactoferrin
Conventionally produced bovine (from cows) lactoferrin has been around for years and is largely used in premium infant formulas.
However, extracting it is a costly and wasteful process. This is because there is very little of it in milk – it accounts for 1% of whey proteins – and so it has to be produced through a process of extraction and filtration that requires vast quantities of whey.
According to Fortune Business Insights, the top five companies driving lactoferrin growth in 2026 are MILEI GmbH (a subsidiary of Morinaga Milk Group), FrieslandCampina Ingredients, Bega Bionutrients, Synlait and Noumi.
It forecasts the market to reach $810.11 million by 2034 with a CAGR of 4.30% over 2026 to 2034.
In Europe, it has been approved as a food ingredient since 2012.
Precision fermentation steps in
Lactoferrin was regarded as an expensive and elusive ingredient but it’s now breaking into the mainstream thanks to precision fermentation arriving on the scene.
It means that it can now be produced using genetically engineered micro-organisms that express the lactoferrin protein, eliminating the need for extracting it from milk, and making it animal-free.
There are two main types of precision-fermented lactoferrin:
Bovine lactoferrin – this is bioidentical to cow’s milk but it’s produced using engineered microbes in a fermentation tank. Recombinant DNA technology is used to cut and paste DNA from one organism – ie a cow – into a host organism such as yeast or fungi to create a genetically modified organism.
Precision fermentation is the industrial brewing process that grows this modified host organism in a controlled tank to express and harvest the specific target molecule – lactoferrin.
Human lactoferrin – bioidentical to the lactoferrin found in human breast milk using the same method as above.
What’s happening in the precision-fermented lactoferrin landscape?
The aim of the companies in this space is to scale up the production of precision-fermented lactoferrin to make it cost-effective and accessible.
So far, the US is the hotbed of activity for bovine lactoferrin.
Singapore-based Turtle Tree was the first company in the space to receive the US Food and Drug Administration (FDA) Generally Recognized As Safe (GRAS) ‘no questions’ status in 2025. This means that the FDA evaluates the evidence submitted by a company, agrees with their safety assessment and issues a formal ‘no questions’ letter.
In July 2026, Novonesis announced a partnership with Turtle Tree to help scale and commercialise it for the early-life nutrition market.
Australian company All G also has a bovine lactoferrin that received an FDA ‘no questions’ letter in April 2026. It’s focusing its sights on the US and China.
Dutch start-up Vivici is newer to the scene but being powered by its founders – New Zealand dairy giant Fonterra and global nutrition and health company DSM-Firmenich – has given it a significant advantage in the path to large-scale manufacturing and it’s positioning itself as being commercially viable.
It has a portfolio of animal-free, precision-fermented animal proteins called Vivitein and this includes a precision-fermented lactoferrin that launched in 2026.
It received self-affirmed GRAS status in the US in February 2026 and was launched commercially in the US market. It has initiated the regulatory approval process in the EU.
It’s inserting itself into the gut health and sports nutrition space, as well as aiming it at women who have low iron.
This is a common theme as Turtle Tree also targets the women’s health space.
In June 2026, Vivici was awarded a €12.5 million grant by the European Innovation Council Accelerator Program grant to help scale up its precision-fermented dairy proteins, including lactoferrin, demonstrating the growing interest in the ingredient.
“The biggest impact of precision fermentation in the food and beverage sector will be creating access to ingredients that aren’t otherwise available.”
Dr James Behrendorff, senior lecturer in microbial biotechnology
Human lactoferrin at scale
Precision-fermented human lactoferrin is a more complex protein to produce but the spotlight is turning towards it as a viable commercial proposition and emerging high-value category. Big names are throwing their weight behind it.
In June 2026, Nestlé entered into a partnership with US biotech firm Helaina to help scale up production of its human lactoferrin product, Effera, which was the first bioidentical human lactoferrin. This is mostly for the infant nutrition space.
Scaling it is being worked on elsewhere too. PFx Biotech in Portugal is focusing on scaling up for commercial use and Queensland University of Technology in Australia is collaborating with Eclipse Ingredients in a $5.5m project to commercialise precision-fermented human lactoferrin.
“The biggest impact of precision fermentation in the food and beverage sector will be creating access to ingredients that aren’t otherwise available,” says Dr James Behrendorff, senior lecturer in microbial biotechnology at Queensland University of Technology, who’s leading the work. “Human lactoferrin protein is an outstanding example of a really important functional protein that we can’t deliver without precision fermentation technology.”
Critically, it’s the same version our bodies naturally make and recognise, says Siobhan Coster, CEO of Eclipse Ingredients.
“Initially, we expect to see it in targeted applications where lactoferrin’s well-documented benefits across immunity, iron absorption and inflammation are most valued - women’s health and sports nutrition are compelling early applications,” she says.
But precision fermentation is also the only way to get human lactoferrin into infant formula at scale, she adds, taking it a step closer to the gold standard of breast milk.
Consumer trust is an issue with precision fermentation, so this will need to be overcome.
“I think there will be good acceptance of human lactoferrin when it is clear that precision fermentation is creating safe and scalable access to the best ingredients,” says Dr Behrendorff. “Arachidonic acid and docosohexanoic acid – fats critical to infant nutrition and brain development – are good examples of important high-function ingredients that are already manufactured via precision fermentation for the dairy-free infant formula sector.”
The future
With investment coming in and technology advancing fast, this is a space to watch for food and beverage as it ticks the functional, animal-free, sustainable boxes that consumers are increasingly demanding.
Vivici dubbed lactoferrin as “the breakthrough protein whose time has come” and that seems to be coming true.
